Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma
- PMID: 40171567
- PMCID: PMC12165550
- DOI: 10.1097/JS9.0000000000002356
Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma
Abstract
Vorasidenib, a dual inhibitor of isocitrate dehydrogenase 1 and 2 (IDH1/2), has shown promise as a therapeutic agent following its recent FDA approval for the treatment of grade 2 astrocytomas and oligodendrogliomas harboring IDH mutations in patients 12 years of age and older following surgery. While Vorasidenib offers significant potential in targeting altered metabolic pathways in low-grade gliomas, its comprehensive toxicologic and safety profile has not been adequately explored. This research letter addresses this critical gap by presenting an in silico analysis of the potential toxicologic effects of Vorasidenib. Using computational tools - ADMETlab 3.0, FAF-Drugs 4.1, DeepPK, vNN-ADMET, Pred-hERG 5.0, ADVERPred, PreADMET, and ADMET-AI - and databases such as ChEMBL, PubChem, and ChemSpider, we evaluated the key physicochemical properties and predicted ADMET profiles of Vorasidenib, along with a comparative analysis of two other drugs, namely Ivosidenib and Enasidenib. Our results suggest potential risks associated with drug-induced liver injury (DILI) and hepatotoxicity, with structural properties indicative of hepatocellular damage during and after treatment. The low clearance rates associated with the low maximum recommended dose suggest that Vorasidenib may accumulate in the bloodstream over time, increasing the likelihood of toxic reactions. In addition, the predictive models indicate concerns for neurotoxicity, nephrotoxicity and cardiotoxicity, including potential blockade of hERG channels leading to QT interval prolongation and cardiac arrhythmias. Importantly, the analysis also indicates risks of genotoxicity and carcinogenicity, raising concerns about promoting additional tumor formation in patients already prone to malignancies. These results emphasize the need for further preclinical and clinical studies to validate the safety of Vorasidenib. A comprehensive understanding of the toxicologic profile is critical to ensure that the therapeutic benefit for patients with IDH1/2-mutated low-grade gliomas is not compromised by potential adverse effects. Careful monitoring of patients and tailored therapeutic strategies are essential to optimize clinical outcomes and guide physicians in the safe use of Vorasidenib in clinical practice.
Keywords: IDH 1/2 inhibition; toxicity; vorasidenib.
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
None declared.
Figures

Similar articles
-
Vorasidenib: First Approval.Drugs. 2024 Oct;84(10):1325-1331. doi: 10.1007/s40265-024-02097-2. Epub 2024 Oct 8. Drugs. 2024. PMID: 39375303 Free PMC article. Review.
-
Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mouse plasma: Application to a pharmacokinetic study.Biomed Chromatogr. 2019 Nov;33(11):e4658. doi: 10.1002/bmc.4658. Epub 2019 Sep 2. Biomed Chromatogr. 2019. PMID: 31325170
-
Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions.Front Oncol. 2025 Jun 27;15:1628195. doi: 10.3389/fonc.2025.1628195. eCollection 2025. Front Oncol. 2025. PMID: 40657255 Free PMC article. Review.
-
Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.Biomedicines. 2025 Jan 15;13(1):201. doi: 10.3390/biomedicines13010201. Biomedicines. 2025. PMID: 39857783 Free PMC article.
-
An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors.Radiother Oncol. 2025 Jan;202:110640. doi: 10.1016/j.radonc.2024.110640. Epub 2024 Nov 16. Radiother Oncol. 2025. PMID: 39557126
References
-
- van den Bent MJ, Chang SM. Grade II and III oligodendroglioma and astrocytoma. Neurol Clinics 2018;36:467–84. - PubMed
-
- Peters KB. Targeting Mutant IDH to Treat Low-grade Glioma. touchREVIEWS in Oncology & Haematology 2023;19:7-11.
-
- Mellinghoff IK, Van Den Bent MJ, Clarke JL, et al. INDIGO: A Global, Randomized, Double-blind, Phase III Study of Vorasidenib (VOR; AG-881) Vs Placebo in Patients (Pts) with Residual or Recurrent Grade II Glioma with an Isocitrate Dehydrogenase 1/2 (IDH1/2) Mutation. ed. American Society of Clinical Oncology; 2020.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous